Literature DB >> 21545189

Do productivity costs matter?: the impact of including productivity costs on the incremental costs of interventions targeted at depressive disorders.

Marieke Krol1, Jocé Papenburg, Marc Koopmanschap, Werner Brouwer.   

Abstract

BACKGROUND: When guidelines for health economic evaluations prescribe that a societal perspective should be adopted, productivity costs should be included. However, previous research suggests that, in practice, productivity costs are often neglected. This may considerably bias the results of cost-effectiveness studies, particularly those regarding treatments targeted at diseases with a high incidence rate in the working population, such as depressive disorders.
OBJECTIVES: This study aimed to, first, investigate whether economic evaluations of treatments for depressive disorders include productivity costs and, if so, how. Second, to investigate how the inclusion or exclusion of productivity costs affects incremental costs.
METHODS: A systematic literature review was performed. Included articles were reviewed to determine (i) whether productivity costs had been included and (ii) whether the studies adhered to national health economic guidelines about the inclusion or exclusion of these costs. For those studies that did include productivity costs, we calculated what proportion of total costs were productivity costs. Subsequently, the incremental costs, excluding productivity costs, were calculated and compared with the incremental costs presented in the original article, to analyse the impact of productivity costs on final results. Regression analyses were used to investigate the relationship between the level of productivity costs and the type of depressive disorder, the type of treatment and study characteristics such as time horizon used and productivity cost valuation method.
RESULTS: A total of 81 unique economic evaluations of treatments for adults with depressive disorders were identified, 24 of which included productivity costs in the numerator and one in the denominator. Approximately 69% of the economic evaluations ignored productivity costs. Two-thirds of the studies complied with national guidelines regarding the inclusion of productivity costs. For the studies that included productivity costs, these costs reflected an average of 60% of total costs per treatment arm. The inclusion or exclusion of productivity costs substantially affected incremental costs in a number of studies. Regression analyses showed that the level of productivity costs was significantly associated with study characteristics such as average age, the methods of data collection regarding work time lost, the values attached to lost work time, the type of depressive disorder, the type of treatment provided and the level of direct costs.
CONCLUSIONS: Studies that do not include productivity costs may, in many cases, poorly reflect full societal costs (or savings) of an intervention. Furthermore, when comparing total costs reported in studies that include productivity costs, it should be noted that study characteristics such as the methods used to assess productivity costs may affect their level.

Entities:  

Mesh:

Year:  2011        PMID: 21545189     DOI: 10.2165/11539970-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  116 in total

1.  The value of mental health care at the system level: the case of treating depression.

Authors:  R G Frank; T G McGuire; S L Normand; H H Goldman
Journal:  Health Aff (Millwood)       Date:  1999 Sep-Oct       Impact factor: 6.301

2.  Comparison of the cost-effectiveness of milnacipran (a SNRI) with TCAs and SSRIs: a modeling approach.

Authors:  R Dardennes; G Berdeaux; A Lafuma; F Fagnani
Journal:  Eur Psychiatry       Date:  1999-06       Impact factor: 5.361

3.  Towards a new approach for estimating indirect costs of disease.

Authors:  M A Koopmanschap; B M van Ineveld
Journal:  Soc Sci Med       Date:  1992-05       Impact factor: 4.634

Review 4.  Health economic evaluations of antidepressants: a review.

Authors:  T R Hylan; D P Buesching; G D Tollefson
Journal:  Depress Anxiety       Date:  1998       Impact factor: 6.505

5.  Evidence into practice. Prescribing selective serotonin reuptake inhibitors.

Authors:  N Freemantle; J M Mason; I Watt
Journal:  Int J Technol Assess Health Care       Date:  1998       Impact factor: 2.188

6.  Effectiveness and cost-effectiveness of antidepressant treatment in primary health care: a six-month randomised study comparing fluoxetine to imipramine.

Authors:  A Serrano-Blanco; E Gabarron; I Garcia-Bayo; M Soler-Vila; E Caramés; M T Peñarrubia-Maria; A Pinto-Meza; J M Haro
Journal:  J Affect Disord       Date:  2006-02-03       Impact factor: 4.839

7.  A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions.

Authors:  Patrick W Sullivan; Robert Valuck; Joseph Saseen; Holly M MacFall
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

8.  Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder.

Authors:  Bruno Fantino; Nicholas Moore; Hélène Verdoux; Jean-Paul Auray
Journal:  Int Clin Psychopharmacol       Date:  2007-03       Impact factor: 1.659

9.  Cost-effectiveness and cost-utility of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine: randomised controlled trial.

Authors:  Tony Kendrick; Robert Peveler; Louise Longworth; David Baldwin; Michael Moore; Judy Chatwin; Andrew Thornett; Jonathan Goddard; Michael Campbell; Helen Smith; Martin Buxton; Christopher Thompson
Journal:  Br J Psychiatry       Date:  2006-04       Impact factor: 9.319

10.  Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria.

Authors:  Michiel E H Hemels; Siegfried Kasper; Evelyn Walter; Thomas R Einarson
Journal:  Curr Med Res Opin       Date:  2004-06       Impact factor: 2.580

View more
  35 in total

1.  Predicting productivity based on EQ-5D: an explorative study.

Authors:  Marieke Krol; Elly Stolk; Werner Brouwer
Journal:  Eur J Health Econ       Date:  2013-06-13

2.  How to include informal care in economic evaluations.

Authors:  Renske J Hoefman; Job van Exel; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2013-12       Impact factor: 4.981

3.  Variation in the methodological approach to productivity cost valuation: the case of prostate cancer.

Authors:  Paul Hanly; Rebecca Maguire; Frances Drummond; Linda Sharp
Journal:  Eur J Health Econ       Date:  2019-08-23

Review 4.  Productivity costs in economic evaluations: past, present, future.

Authors:  Marieke Krol; Werner Brouwer; Frans Rutten
Journal:  Pharmacoeconomics       Date:  2013-07       Impact factor: 4.981

5.  How to estimate productivity costs in economic evaluations.

Authors:  Marieke Krol; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2014-04       Impact factor: 4.981

Review 6.  Friction Cost Estimates of Productivity Costs in Cost-of-Illness Studies in Comparison with Human Capital Estimates: A Review.

Authors:  Jamison Pike; Scott D Grosse
Journal:  Appl Health Econ Health Policy       Date:  2018-12       Impact factor: 2.561

Review 7.  Transferability of indirect cost of chronic disease: a systematic review and meta-analysis.

Authors:  Fei-Li Zhao; Feng Xie; Hao Hu; Shu-Chuen Li
Journal:  Pharmacoeconomics       Date:  2013-06       Impact factor: 4.981

8.  Valuing productivity costs in a changing macroeconomic environment: the estimation of colorectal cancer productivity costs using the friction cost approach.

Authors:  Paul Hanly; Marc Koopmanschap; Linda Sharp
Journal:  Eur J Health Econ       Date:  2015-05-29

9.  Cost-utility analysis of a collaborative care intervention for major depressive disorder in an occupational healthcare setting.

Authors:  Maartje Goorden; Moniek C Vlasveld; Johannes R Anema; Willem van Mechelen; Aartjan T F Beekman; Rob Hoedeman; Christina M van der Feltz-Cornelis; Leona Hakkaart-van Roijen
Journal:  J Occup Rehabil       Date:  2014-09

10.  Estimated annual and lifetime labor productivity in the United States, 2016: implications for economic evaluations.

Authors:  Scott D Grosse; Kurt V Krueger; Jamison Pike
Journal:  J Med Econ       Date:  2018-11-15       Impact factor: 2.448

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.